Retrospective study of unresectable stage III or stage IV melanoma refractory to immune checkpoint and BRAF/MEK inhibitors, treated with triplet vs doublet therapy: A single institution experience.

Authors: Hariharasudan Mani, Nicole Nester, Grace Rauscher, Timothy Johnson, Zeeshan Hafeez, Darshan Lal, Colby Presley, Hope Kincaid, Alyson McIntosh, Aaron Blackham, Suresh Nair

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e21500

Source: Full article

---

Abstract

e21500